Clinical Trial: ROLE OF N-ACETYLCYSTEINE IN NON-ACETAMINOPHEN-INDUCED LIVER FAILURE

U.S., Aug. 15 -- ClinicalTrials.gov registry received information related to the study (NCT07765823) titled 'ROLE OF N-ACETYLCYSTEINE IN NON-ACETAMINOPHEN-INDUCED LIVER FAILURE' on Aug. 10.

Brief Summary: This randomized controlled trial evaluates whether oral N-acetylcysteine (NAC), given alongside standard supportive care, improves survival and reduces mortality in patients with non-acetaminophen-induced acute liver failure (ALF), compared to supportive care alone. Secondary objectives are to assess NAC's effect on length of hospital stay and improvement in liver function tests. Sixty-two adult patients (18-60 years) will be randomized 1:1 to NAC or control, with outcomes assessed at 28 days (survival/mortality) and day 4 (liver function...